Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patidegib - Sol-Gel Technologies

X
Drug Profile

Patidegib - Sol-Gel Technologies

Alternative Names: BBP-009; FIN-5; IPI-926; Patidegib topical gel - PellePharm; Patidegib-hydrochloride; Saridegib; Saridegib-hydrochloride; SGT-610

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Infinity Pharmaceuticals
  • Developer Infinity Pharmaceuticals; PellePharm; Sol-Gel Technologies
  • Class Antineoplastics; Naphthols; Pyridines; Small molecules; Spiro compounds; Sulfonamides; Veratrum alkaloids
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chondrosarcoma; Basal cell nevus syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Basal cell cancer; Basal cell nevus syndrome
  • Discontinued Chondrosarcoma; Head and neck cancer; Myelofibrosis; Pancreatic cancer

Most Recent Events

  • 30 Nov 2023 Phase-III clinical trials in Basal cell cancer in Europe (Topical) (NCT06050122)
  • 30 Nov 2023 Sol-Gel Technologies initiates enrolment in a phase III trial for Basal Cell Nevus Syndrome in the United Kingdome (Topical) (NCT06050122)
  • 30 Nov 2023 Phase-III clinical trials in Basal Cell Nevus Syndrome in North America (Topical) (NCT06050122)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top